share_log

RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10

RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10

加拿大皇家银行资本上调BioCryst Pharma至跑赢大盘,目标股价上调至10美元
Benzinga ·  2023/09/18 07:16

RBC Capital analyst Brian Abrahams upgrades BioCryst Pharma (NASDAQ:BCRX) from Sector Perform to Outperform and raises the price target from $9 to $10.

加拿大皇家银行资本分析师Brian Abrahams将BioCryst Pharma(纳斯达克:BCRX)的评级从行业表现上调至表现优于大盘,并将目标价从9美元上调至10美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发